Physician profile
Simone Hall
NPI 1902149438
$3,412.66
in general payments reported to CMS, 2019-2025
18 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $841 · 2022: $745 · 2023: $618 · 2024: $741 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $580.61 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $430.26 | 2021-2024 | Trintellix |
| Corium, LLC | $378.82 | 2022-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $296.29 | 2024-2025 | Caplyta |
| Abbvie INC. | $280.33 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $253.24 | 2021-2022 | |
| Bausch Health US, LLC | $182.43 | 2021-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $176.66 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $164.87 | 2024-2025 | Qelbree |
| Lundbeck LLC | $150.73 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $146.07 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $125.00 | 2022 | |
| Biogen, INC. | $80.33 | 2023 | |
| Alkermes, INC. | $76.44 | 2022 | |
| Ironshore Pharmaceuticals INC. | $27.29 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $24.99 | 2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $19.50 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $18.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simone Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.